SBRT With Atezo/Bev for HCC
NCT05488522
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL:
SBRT + atezolizumab and bevacizumab
Sponsor
Abramson Cancer Center at Penn Medicine